Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.50 |
| ▸ | CCNK | O75909 | 11/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.45 |
| ▸ | CDK2 | P24941 | 6/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 4/20 | 0.42 |
| ▸ | CCNH | P51946 | 4/20 | 0.42 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.40 |
| ▸ | CDK9 | P50750 | 4/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479217 | 0.90 | EIF2AK2 (0.54) | EIF2AK2CCNKCDK12CDK2CCNE1 | |
| SCHEMBL13638686 | 0.85 | IKBKB (0.47) | EIF2AK2CCNKCDK12CDK2CCNE1 | |
| SCHEMBL13638683 | 0.82 | MAPK8 (0.48) | EIF2AK2CCNKCDK12CDK2CCNE1 | |
| SCHEMBL13638484 | 0.80 | MAPK8 (0.46) | CCNKCDK12CDK2CCNE1MAPK8 | |
| SCHEMBL13638684 | 0.80 | GSK3B (0.48) | EIF2AK2CCNKCDK12CDK2CCNE1 | |
| SCHEMBL13638487 | 0.79 | GSK3B (0.52) | EIF2AK2CCNKCDK12CDK2CCNE1 | |
| SCHEMBL13638594 | 0.79 | MAPK8 (0.61) | EIF2AK2CCNKCDK12CDK2CCNE1 | |
| SCHEMBL13638595 | 0.78 | CCNK (0.49) | CCNKCDK12CDK2CCNE1MAPK8 | |
| SCHEMBL13638445 | 0.78 | CDK2 (0.48) | EIF2AK2CCNKCDK12CDK2CCNE1 | |
| SCHEMBL13638483 | 0.76 | CDK2 (0.43) | EIF2AK2CCNKCDK12CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | EIF2AK2 108/4885CCNK 1085/4885CDK12 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.